Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK) aims to propel future innovation for patients with solid tumors MSK’s Christopher A. Klebanoff, M.D., to serve Affini-T as Scientific Co-founder and Advisor BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced … [Read more…]

Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET

BOSTON–(BUSINESS WIRE)–$AKLI #ADHD–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com … [Read more…]

Ventus Therapeutics to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference

WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2023 Bloom Burton & Co. … [Read more…]

Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies

TCR and CAR libraries enable comprehensive screening of combinations of custom gene parts including domains from TCRs and CARs Information about the offering available at AACR Annual Meeting 2023 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, … [Read more…]

Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating … [Read more…]

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

Top-Line Results Expected in the First Half of 2023 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced completion of enrollment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of allergic conjunctivitis. “Today, millions of allergic conjunctivitis patients rely on therapies that … [Read more…]

Sixteen US Eye Physicians Named to Castle Connolly’s 2023 Top Doctors List

SARASOTA, Fla.–(BUSINESS WIRE)–#Eyecare–US Eye, a patient-centric network of premium eye care practices, is proud to announce that sixteen US Eye physicians have been named to the 2023 list of Top Doctors published by Castle Connolly Medical, Ltd. Castle Connolly Top Doctors are peer-nominated, and thoroughly vetted by a physician-led research team. The Castle Connolly research … [Read more…]

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/606,856, titled “Engineered meganucleases specific for recognition … [Read more…]

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

New Technology Provides Cutting Edge Visualization, Ergonomic Positioning and Efficient Workflow VAUGHAN, Ontario & HEIDELBERG, Germany–(BUSINESS WIRE)–Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a … [Read more…]

Vizient Examines Care Models for Arrhythmia, How to Improve Screening Rates for Colorectal Cancer in Latest Medical Device Tech Watch

IRVING, Texas–(BUSINESS WIRE)–#Afib—Vizient, Inc. released its latest Medical Device Tech Watch, examining care models for cardiac arrhythmia, methods for improving colorectal cancer screening rates and how optimizing surgical tray standardization can reduce costs and improve operational efficiencies. Access Medical Device Tech Watch. “This edition of Tech Watch explores a variety of topics, including emerging artificial … [Read more…]